Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Status:
Not yet recruiting
Trial end date:
2030-06-28
Target enrollment:
Participant gender:
Summary
A open-label, multicenter, phase IIIb, single-arm trial is to evaluate the efficacy of the
combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast
cancer-free survival (iBCFS), in close to real world patient population with HR-positive,
HER2-negative, Anatomic Stage Group III, IIB or a subset of Stage IIA early Breast Cancer
(EBC).